Comparative Pharmacology
Head-to-head clinical analysis: BIAXIN versus ERY TAB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BIAXIN versus ERY TAB.
BIAXIN vs ERY-TAB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 50S ribosomal subunit, inhibiting bacterial protein synthesis by blocking peptide chain elongation.
Erythromycin binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation step.
250-500 mg orally every 12 hours for 7-14 days; extended-release: 1000 mg orally every 24 hours for 7-14 days
250-500 mg orally every 6 hours or 333-666 mg every 8 hours. Maximum 4 g/day.
None Documented
None Documented
Terminal elimination half-life: 3-7 hours (single dose, 250-500 mg); with multiple dosing, half-life may extend to 7-10 hours due to saturable metabolism. Clinical context: Shorter half-life requires twice-daily dosing; extended half-life (via 14-hydroxy metabolite, t1/2 ~11 h) contributes to antibacterial activity.
The terminal elimination half-life of erythromycin base is approximately 1.5-2 hours in patients with normal renal function. In patients with end-stage renal disease, the half-life may be prolonged to 4-6 hours. The half-life is not significantly altered in hepatic impairment, but accumulation can occur with severe liver disease.
Approximately 20-30% of administered dose is excreted unchanged in urine; remainder is hepatically metabolized and excreted in bile and feces (~50% fecal elimination).
Erythromycin is primarily excreted in bile as active drug and metabolites, with approximately 12-15% of an administered dose excreted unchanged in urine. Fecal elimination accounts for about 30-60% of the dose, largely due to biliary excretion.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic